Apollomics AI Stock Analysis
Want to see APLM full AI Analyst Report?
Apollomics (APLM) AI Stock Analysis
Apollomics
(NASDAQ:APLM)
APLM scores near the bottom of the range, driven primarily by a fragile financial position: negative shareholders' equity, a shrinking asset base of only $6.7M, zero gross profit on newly recognized revenue, and ongoing cash burn of roughly $10M a year that likely necessitates dilutive financing. Technical signals reinforce the caution, with the stock trading below its 20-, 50- and 100-day moving averages alongside a negative MACD and soft RSI. Valuation offers no cushion given negative earnings and no dividend. The one encouraging element is the sharp year-over-year reduction in losses and cash outflows, suggesting improved cost discipline, but this is not yet enough to offset substantial balance sheet and liquidity risk in this early-stage biotech.
Apollomics (APLM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $52.00M
- Dividend Yield
- ―
- Average Volume (3M)
- 12.68K
- Price to Earnings (P/E)
- -65.9
- Beta (1Y)
- 0.94
- Revenue Growth
- -100.00%
- EPS Growth
- 99.08%
- Country
- US
- Employees
- 14
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Apollomics Business Overview & Revenue Model
Company Description
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to d...
Apollomics Financial Statement Overview
Summary
Financial health is very weak across all three statements. The income statement (score 12) shows persistent, deep unprofitability with a -129% net margin in 2025, and although revenue jumped to $8.5M and losses narrowed sharply to ~$10.9M, gross profit fell to zero, undermining the quality of that revenue. The balance sheet (score 8) is the biggest concern: stockholders' equity turned negative at -$3.2M and total assets collapsed from $55.4M in 2023 to just $6.7M, pointing to going-concern and dilution risk despite low absolute debt of $643K. Cash flow (score 15) remains negative at -$10.4M operating and free cash flow, though improved from -$28.7M a year earlier. The narrowing losses and tighter cost base are genuine positives, but liquidity and solvency risks dominate.
Income Statement
12Very NegativeBalance Sheet
8Very NegativeCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.50M | 8.50M | 198.00K | 821.00K | 323.00K | 2,000 |
| Gross Profit | 8.50M | 8.24M | 198.00K | 821.00K | 323.00K | 2,000 |
| EBITDA | -9.36M | -9.22M | -40.77M | -52.88M | -43.29M | -49.59M |
| Net Income | -10.94M | -10.94M | -53.86M | -172.60M | -240.81M | -94.80M |
Balance Sheet | ||||||
| Total Assets | 6.71M | 6.71M | 13.10M | 55.39M | 76.47M | 123.44M |
| Cash, Cash Equivalents and Short-Term Investments | 3.28M | 3.28M | 9.77M | 37.82M | 54.61M | 94.48M |
| Total Debt | 643.00K | 643.00K | 966.00K | 4.66M | 991.00K | 325.41M |
| Total Liabilities | 9.90M | 9.90M | 8.23M | 14.15M | 524.60M | 336.30M |
| Stockholders Equity | -3.19M | -3.19M | 4.86M | 41.23M | -448.12M | -212.86M |
Cash Flow | ||||||
| Free Cash Flow | -17.99M | -10.37M | -28.77M | -43.22M | -43.19M | -50.86M |
| Operating Cash Flow | -17.99M | -10.37M | -28.74M | -43.21M | -42.82M | -43.31M |
| Investing Cash Flow | 266.00K | 218.00K | 5.98M | 21.36M | 29.05M | -38.95M |
| Financing Cash Flow | 3.59M | 3.68M | 468.00K | 21.23M | -294.00K | -1.64M |
Apollomics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APLM, the sentiment is Negative. The current price of 17.84 is below the 20-day moving average (MA) of 19.67, below the 50-day MA of 21.62, and below the 200-day MA of 18.92, indicating a bearish trend. The MACD of -1.16 indicates Positive momentum. The RSI at 38.42 is Neutral, neither overbought nor oversold. The STOCH value of 17.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APLM.
Apollomics Peers Comparison
Overall Rating
GDTC43Neutral
XCUR42Neutral
CLGN41Neutral
APLM40Underperform
HIND39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $9.16M | -2.27 | -91.37% | ― | 49.09% | 3.91% | |
| 42Neutral | $7.00M | -0.83 | -237.91% | ― | ― | 23.05% | |
| 41Neutral | $6.90M | -0.49 | -215.58% | ― | -86.76% | 16.63% | |
| 40Underperform | $52.00M | -65.88 | 103.09% | ― | -100.00% | 99.08% | |
| 39Underperform | $10.74M | -2.51 | -73.13% | ― | -96.35% | 99.68% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| APLM | Apollomics Inc. | 17.84 | -0.04 | -0.22% | |
| HIND | Vyome Holdings, Inc. | 1.53 | -3.08 | -66.81% | |
| CLGN | CollPlant Biotechnologies Ltd. | 3.65 | -17.75 | -82.94% | |
| XCUR | Exicure | 1.07 | -3.67 | -77.43% | |
| GDTC | CytoMed Therapeutics Limited | 0.77 | -1.04 | -57.29% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
